FGFR1 Induces Acquired Resistance Against Gefitinib By Activating AKT/mTOR Pathway In NSCLC

OBJECTIVE: As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dan, Han, Li-li, Du, Fen, Liu, Xiao-meng, Li, Jin, Wang, Hui-hui, Song, Ming-hui, Li, Zeng, Li, Guo-yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874148/
https://www.ncbi.nlm.nih.gov/pubmed/31819480
http://dx.doi.org/10.2147/OTT.S220462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874148/
https://www.ncbi.nlm.nih.gov/pubmed/31819480
http://dx.doi.org/10.2147/OTT.S220462

Ejemplares similares